5D Library › The Default Mode Network, the Entropic Brain and Neural Oscillations · 中文

Chapter 3 The 5-HT2A Receptor and the Entropic Brain

Note

Legal and medical notice for this chapter. Psilocybin, psilocin and related tryptamines are controlled substances. In Malaysia they are listed in Part III of the First Schedule of the Dangerous Drugs Act 1952; in China they are listed as controlled psychotropic substances; and they are in Schedule I of the United Nations Convention on Psychotropic Substances of 1971. Possessing, producing, supplying or using them is a serious offence in these and most other jurisdictions; a small number of jurisdictions allow medical use only within tightly regulated programmes, for example prescription by authorised psychiatrists in Australia since July 2023. They carry real risks: acute anxiety and panic, confusion, raised blood pressure and heart rate, and, in people with a personal or family history of psychosis or bipolar disorder, the risk of triggering a serious psychiatric illness. This chapter reviews clinical research only to understand the mechanism of the 5-HT2A receptor and the default mode network. It does not advise, encourage or describe obtaining or using any controlled substance, and it gives no doses. The practices this book recommends, in Chapters 4 and 8, use no substance of any kind.

A receptor for serotonin

Serotonin (5-hydroxytryptamine, 5-HT) acts on at least fourteen receptor types. One of them, the 5-HT2A receptor, is especially dense on the large pyramidal neurons of cortical layer 5, whose outputs connect cortical areas to each other and to deeper structures. Classic psychedelic substances, including psilocin (the active form of psilocybin), LSD and mescaline, are agonists at this receptor, and in human studies blocking it with an antagonist such as ketanserin largely prevents their subjective effects (Vollenweider et al. 1998; Nichols 2016).

How tightly a molecule binds

The basic quantitative tool of receptor pharmacology is the binding curve. If a ligand binds reversibly to a receptor, then at equilibrium the fraction of receptors occupied depends on the free concentration cc and the dissociation constant KdK_d, the concentration at which half the receptors are occupied:

occupancy=cnKdn+cn\text{occupancy} = \frac{c^n}{K_d^{\,n} + c^n}

This is the Hill–Langmuir equation; nn, the Hill coefficient, is 1 for simple one-to-one binding and greater than 1 when binding is cooperative. A competitive antagonist shifts the curve to the right, raising the apparent KdK_d by a factor 1+I/Ki1 + I/K_i.

Calculation

Occupancy against concentration, in units of KdK_d, and the effect of a competitive antagonist. The program is written in dimensionless units on purpose: it describes the shape of binding, not any amount of any substance.

# Receptor occupancy by the Hill–Langmuir equation, in units of the
# dissociation constant Kd (concentration / Kd). No doses: the numbers are
# dimensionless and say nothing about any amount a person might take.

def occupancy(c, kd=1.0, n=1.0):
    """Fraction of receptors bound at free ligand concentration c."""
    return c ** n / (kd ** n + c ** n)

print("c/Kd   occupied (n = 1)   occupied (n = 2)")
for c in (0.1, 0.3, 1, 3, 10):
    print(f"{c:4g}   {occupancy(c):16.2f}   {occupancy(c, n=2):16.2f}")

# A competitive antagonist at concentration I with its own constant Ki
# shifts the agonist curve: apparent Kd' = Kd (1 + I/Ki).
for i_over_ki in (0, 1, 9):
    kd_app = 1 + i_over_ki
    print(f"antagonist I/Ki = {i_over_ki}: apparent Kd × {kd_app:g}, "
          f"occupancy at c/Kd = 1 is {occupancy(1, kd_app):.2f}")
# c/Kd   occupied (n = 1)   occupied (n = 2)
#  0.1               0.09               0.01
#  0.3               0.23               0.08
#    1               0.50               0.50
#    3               0.75               0.90
#   10               0.91               0.99
# antagonist I/Ki = 0: apparent Kd × 1, occupancy at c/Kd = 1 is 0.50
# antagonist I/Ki = 1: apparent Kd × 2, occupancy at c/Kd = 1 is 0.33
# antagonist I/Ki = 9: apparent Kd × 10, occupancy at c/Kd = 1 is 0.09

Occupancy is not effect. What a receptor does when occupied depends on the ligand’s efficacy and on which intracellular pathways it favours, a property called functional selectivity or biased agonism. This is one reason why molecules that bind the same receptor can have very different effects, and why binding numbers alone cannot predict experience (Nichols 2016).

Measuring the richness of a signal

The “entropic brain” hypothesis uses ideas from information theory. Two measures are common. Shannon entropy asks how unpredictable the symbols of a signal are, given how often each occurs. Lempel–Ziv complexity asks how many new patterns appear as one reads through a signal; a perfectly regular signal can be described with few patterns, a random one needs many.

Calculation

Lempel–Ziv complexity and the entropy of three-symbol words for three synthetic signals: a pure 10 Hz rhythm, the same rhythm with noise, and noise alone. Each signal is turned into a string of 0s and 1s by splitting at its median.

import math, random

def lz76(s):
    """Number of phrases in the Lempel–Ziv (1976) parsing of a 0/1 string."""
    i, c, n = 0, 0, len(s)
    while i < n:
        k = 1
        while i + k <= n and s[i:i + k] in s[:i + k - 1]:
            k += 1
        c += 1
        i += k
    return c

def binarise(x):
    m = sorted(x)[len(x) // 2]                      # split at the median
    return "".join("1" if v > m else "0" for v in x)

def entropy_words(s, L=3):
    """Shannon entropy (bits) of the 3-symbol words in the string."""
    counts = {}
    for i in range(len(s) - L + 1):
        counts[s[i:i + L]] = counts.get(s[i:i + L], 0) + 1
    tot = sum(counts.values())
    return -sum(c / tot * math.log2(c / tot) for c in counts.values())

rnd = random.Random(7)
n, fs = 2000, 250                                  # 8 s at 250 samples per second
t = [i / fs for i in range(n)]
signals = {
    "10 Hz rhythm":            [math.sin(2 * math.pi * 10 * u) for u in t],
    "10 Hz rhythm + noise":    [math.sin(2 * math.pi * 10 * u) + 0.8 * rnd.gauss(0, 1) for u in t],
    "noise only":              [rnd.gauss(0, 1) for _ in t],
}
norm = n / math.log2(n)                            # LZ count of a random string, roughly
print("signal                  LZ (normalised)   entropy of 3-bit words")
for name, x in signals.items():
    s = binarise(x)
    print(f"{name:22s}   {lz76(s) / norm:14.2f}   {entropy_words(s):10.2f} of 3.00 bits")
# signal                  LZ (normalised)   entropy of 3-bit words
# 10 Hz rhythm                       0.07         1.79 of 3.00 bits
# 10 Hz rhythm + noise               0.84         2.75 of 3.00 bits
# noise only                         1.05         3.00 of 3.00 bits

The output makes a point that is easy to miss: the highest complexity belongs to pure noise. More entropy is not, in itself, a better or richer state. A brain that showed maximum entropy would be a brain whose activity carried no structure at all. Whatever value the measures have depends on comparison with the right baseline and on what else changes at the same time.

The imaging findings

Evidence

In functional MRI studies with intravenous psilocybin in healthy volunteers, Carhart-Harris and colleagues found only decreases in blood flow and BOLD signal, largest in hub regions including the thalamus, the anterior and posterior cingulate cortex and the medial prefrontal cortex; the decrease in medial prefrontal activity tracked the intensity of the subjective effects, and the positive coupling between the medial prefrontal and posterior cingulate cortex was weakened (Carhart-Harris et al. 2012). In magnetoencephalography, psychoactive doses of psilocybin, LSD and ketamine all increased the Lempel–Ziv complexity of spontaneous brain signals compared with placebo (Schartner et al. 2017).

From findings like these Carhart-Harris and colleagues proposed the entropic brain hypothesis: that the quality of conscious states can be indexed by the entropy of brain activity, with ordinary waking consciousness held in a relatively constrained, lower-entropy regime by the integrating activity of the default network, and with psychedelic states as higher-entropy states in which that constraint is relaxed (Carhart-Harris et al. 2014). A later version, “relaxed beliefs under psychedelics” (REBUS), recast this in the language of predictive processing: the substances are proposed to weaken the precision of high-level prior beliefs, letting bottom-up information have more influence (Carhart-Harris and Friston 2019).

Evidence

In laboratory and animal studies, psychedelics increase the growth of dendrites and synapses in cortical neurons (Ly et al. 2018). A 2023 study reported that LSD and psilocin also bind directly to TrkB, the receptor for brain-derived neurotrophic factor (BDNF), and that the plasticity and antidepressant-like effects in mice depended on this binding rather than on 5-HT2A activation (Moliner et al. 2023). These are findings in cells and mice; how far they apply to people is not known.

The clinical evidence and its limits

Evidence

In a double-blind study at Johns Hopkins University, healthy volunteers given psilocybin under supportive, supervised conditions often rated the experience as among the most personally meaningful of their lives; at the same time, about a third reported significant fear during the session, and some had episodes of anxiety or paranoid thinking (Griffiths et al. 2006).

Evidence

In a randomised trial in 233 people with treatment-resistant depression, a single high dose of psilocybin given with psychological support reduced depression scores at three weeks more than a very low control dose (difference −6.6 points on the MADRS, 95 % CI −10.2 to −2.9); adverse events occurred in 77 % of participants, mostly headache, nausea and dizziness, and suicidal ideation or behaviour or self-injury occurred in all dose groups (Goodwin et al. 2022). In a trial of 59 people with moderate to severe depression, psilocybin with support was not shown to be better than six weeks of the antidepressant escitalopram on the primary outcome (Carhart-Harris et al. 2021).

The limits of this evidence are substantial and are acknowledged by the researchers. Blinding is very hard, because participants usually know whether they have received an active substance, and expectations are high. Trials are small and short, and the people enrolled are carefully selected: guidelines for research exclude people with a personal or family history of psychotic disorders, and people with significant cardiovascular disease, and provide preparation, supervision throughout the session and follow-up (Johnson et al. 2008). Results under those conditions say nothing about use outside them, which carries the legal and medical risks set out at the start of this chapter.

Hypothesis · not established

Not established. The aspect of the psychedelic state that is relevant to well-being is not the rise in entropy itself but the temporary loosening of the default network’s habitual self-referential loops, which may also be reachable by trained attention without any substance. The hypothesis predicts that, in comparable people, measures of default-network integration that fall during psilocybin sessions in clinical studies also fall, by a smaller amount, during sustained focused-attention meditation, while signal complexity does not rise in the same way. It would be refuted if meditation produced no reduction in default-network integration in such a comparison.

References

Carhart-Harris, R. L., D. Erritzoe, T. Williams, et al. 2012. “Neural Correlates of the Psychedelic State as Determined by fMRI Studies with Psilocybin.” Proceedings of the National Academy of Sciences 109 (6): 2138–43.
Carhart-Harris, R. L., and K. J. Friston. 2019. “REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.” Pharmacological Reviews 71 (3): 316–44.
Carhart-Harris, R., B. Giribaldi, R. Watts, et al. 2021. “Trial of Psilocybin Versus Escitalopram for Depression.” New England Journal of Medicine 384 (15): 1402–11.
Carhart-Harris, Robin L., Robert Leech, Peter J. Hellyer, et al. 2014. “The Entropic Brain: A Theory of Conscious States Informed by Neuroimaging Research with Psychedelic Drugs.” Frontiers in Human Neuroscience 8: 20.
Goodwin, Guy M., Scott T. Aaronson, Oscar Alvarez, et al. 2022. “Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.” New England Journal of Medicine 387 (18): 1637–48.
Griffiths, R. R., W. A. Richards, U. McCann, and R. Jesse. 2006. “Psilocybin Can Occasion Mystical-Type Experiences Having Substantial and Sustained Personal Meaning and Spiritual Significance.” Psychopharmacology 187 (3): 268–83.
Johnson, M. W., W. A. Richards, and R. R. Griffiths. 2008. “Human Hallucinogen Research: Guidelines for Safety.” Journal of Psychopharmacology 22 (6): 603–20.
Ly, C., A. C. Greb, L. P. Cameron, et al. 2018. “Psychedelics Promote Structural and Functional Neural Plasticity.” Cell Reports 23 (11): 3170–82.
Moliner, R., M. Girych, C. A. Brunello, et al. 2023. “Psychedelics Promote Plasticity by Directly Binding to BDNF Receptor TrkB.” Nature Neuroscience 26: 1032–41.
Nichols, David E. 2016. “Psychedelics.” Pharmacological Reviews 68 (2): 264–355.
Schartner, Michael M., Robin L. Carhart-Harris, Adam B. Barrett, Anil K. Seth, and Suresh D. Muthukumaraswamy. 2017. “Increased Spontaneous MEG Signal Diversity for Psychoactive Doses of Ketamine, LSD and Psilocybin.” Scientific Reports 7: 46421.
Vollenweider, F. X., M. F. Vollenweider-Scherpenhuyzen, A. Bäbler, H. Vogel, and D. Hell. 1998. “Psilocybin Induces Schizophrenia-Like Psychosis in Humans via a Serotonin-2 Agonist Action.” NeuroReport 9 (17): 3897–902.

Fan, Y. (2026). The Default Mode Network, the Entropic Brain and Neural Oscillations: 5-HT2A Receptor Kinetics, Pineal Calcite Microcrystals and the Computational Neuroscience of Meditative Attention [默认模式网络、熵脑与神经振荡] (Version 1.0.0). 5D Library. https://doi.org/10.5281/zenodo.23697320 · Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).